Dew--How does the GTC patent affect Cogenesys' EPO-alubumin molecule. Does either side have a dominant IP position? HGSI (now Cogenesys) via tech from the Principia (sp?) purchase has developed a number of Albu-fusion molecules with the interferon for hepatitis being the most advanced. Why have albu-EPO, albu-GCSF, etc. failed to start clinical trials--lack of partnership, lack of $$$, IP issues, etc? I'm suprised that development has been so slow because development should be straightforward and the market opportunity is large.
biophud
Market Data 
Markets 
AI
